NCT06258148View on ClinicalTrials.gov

A Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes Mellitus

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

465

Participants

Timeline

Start Date

March 15, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

November 30, 2026

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

TG103

TG103 injection, 7.5mg, 15 mg, SC, once a week

DRUG

Placebo

Placebo, SC, once a week

Trial Locations (1)

100032

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

INDUSTRY

NCT06258148 - A Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter